Establishment of white poplar clonal plantations by stools

The results of white poplar clonal plantation establishment by stools are presented. The trials were established at three sites, characterized by favorable water regime for growth and development of poplars. Also, the effect of different factors on survival rate, diameter at breast height and plants' height was analyzed. Results suggest that similar high survival rate (90-100%) was achieved by planting of stools on depth of 2.5 m (deep planting), as it was achieved by planting of rooted cuttings at the depth of 0.8 m, which is a comon practise in the establishment of white poplar plantations. The survival rate of planted stools did not decrease signifficantly between the end of the first and second growing season. Selected clones achieved survival rate of Villafranca clone with both methods of planting. Two-year old rootless shoots (2/0 type of plantings) achieved higher survival rate than the one-year old ones (1/0 type) and two-year old rooted cuttings (2/2 type). Survival rate of one-year old rootless shoots (1/0 type) planted at the depth of 0.8 m was not significantly lower than of those planted at the depth of 2.5 m, but it was notably lower than survival rate of rooted cuttings (1/1 type). Establishment of white poplar clones by stools could significantly improve white poplar wood production, considering the benefits of plants production in stool beds. The potential for improvement of the establishment of white poplar plantations on sandy soils with relatively deep level of underground water, and the potential for successful planting of difficult-to-root white poplar genotypes, should be the subject of further studies.

Download Full-text

Renal Transplantation—A Tale of Two Cities

Scottish Medical Journal ◽

10.1177/003693308002500404 ◽

1980 ◽

Vol 25 (4) ◽

pp. 269-274

Author(s):

R. F. M. Wood ◽

P. R. F. Bell ◽

J. Walls ◽

J. R. Nash ◽

D. S. MacPherson ◽

...

Keyword(s):

Renal Transplantation ◽

Survival Rate ◽

Graft Survival ◽

Initial Experience ◽

Tissue Typing ◽

Two Cities ◽

Transplant Team ◽

The Difference ◽

One Year ◽

The One

In 1974 three members of the transplant team from the Western Infirmary in Glasgow moved to the new medical school in Leicester. The initial experience with 33 patients transplanted in Glasgow was published in 1972 and this paper compares the results of that series with the first 21 patients grafted in Leicester. Despite improvements in tissue typing, better quality donor kidneys and fewer complications, there has been a failure to improve on the levels of graft survival. The overall one year graft survival rate in the Glasgow series was 79 per cent compared to 52 per cent in Leicester. In these two series the difference in results appears to be explained by blood transfusion. All the Glasgow patients had been poly-transfused but of the Leicester patients the 10 transfused pre-transplant had a one year graft survival of 90 per cent while in the 11 non-transfused patients the one year graft survival was only 18 per cent.

Download Full-text

Gemcitabine, oxaliplatin and weekly high-dose 5-FU as a 24-hr-infusion in chemonaive patients with advanced or metastatic carcinoma of the gallbladder: Preliminary results of a multicenter phase II-study

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.4129 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 4129-4129 ◽

Cited By ~ 2

Author(s):

A. D. Wagner ◽

P. Buechner-Steudel ◽

H. Schmalenberg ◽

M. Moehler ◽

O. Kuss ◽

...

Keyword(s):

Survival Rate ◽

Median Survival ◽

Phase Ii ◽

Tumor Response ◽

Phase Ii Study ◽

Metastatic Carcinoma ◽

Phase Iii ◽

Carcinoma Of The Gallbladder ◽

One Year ◽

The One

4129 Background: Combinations of gemcitabine (GEM)/5-FU, GEM/oxaliplatin (LOHP) or 5-FU/LOHP work synergistically in pancreatic and/or colorectal malignancies, and have non-overlapping safety profiles. This phase II-study was designed to evaluate the efficacy and safety of the triple combination GEM/LOHP/5-FU in patients (pts) with advanced or metastatic carcinoma of the gallbladder. Methods: One-stage, multicentre phase II study. Eligibility criteria: chemonaive pts with histologically proven advanced, recurrent or metastatic gallbladder carcinoma (ECOG 0–1; expected survival >3 months; measurable disease; adequate renal, hepatic and bone marrow function). According to the results of our previous phase I-study (Proc ASCO 2003, # 1298), pts were treated with GEM 900mg/m2 as a 30-min infusion, followed by LOHP 65 mg/m2 (2-hr infusion) after a 30 min rest and 5-FU 1500 mg/m2 (24-hr-infusion) on d 1, 8, every 3 weeks. Planned sample size: 35 response evaluable patients. The primary endpoint was tumor response, secondary endpoints were toxicity, median survival, the one-year-survival rate, clinical benefit and quality of life. Results: At time of abstract submission, median follow-up of 35 enrolled pts is 9.8 months. Pt. characteristics: m/f: 11/24, median age 61 (range 42–81), ECOG 0/1: 24/11 (69/31%) pts, locally advanced/metastatic disease 1/32 (3/91%) pts. Analysis of tumor response is still pending. Grade III/IV (NCI-CTC) toxicities occurred in 36/3% of 191 cycles and were: leucopenia 3/1%, neutropenia 4/1%, thrombocytopenia 4/1%, anemia 2/0%, nausea 1/0%, sensory neuropathy 4/0%, asthenia 1/0%, elevated bilirubin 2/0%, AP 4/0%, or elevated SGOT/SGPT 1/0%, edema 1/0%, infection 1/0%, dyspnoe 1/1%. Median survival of all pts is 9.9 months (95% CI: 7.5–11.5), the one-year-survival-rate is 30 % (95% CI: 16–47). Conclusions: GEM/LOHP/5-FU combination therapy is tolerated well in patients with gallbladder cancer. The promising survival data has to be confirmed in a phase III study. (Supported by grants from Eli Lilly and Company, Indianapolis, IN, USA and Sanofi-Synthelabo, Paris, France). [Table: see text]

Download Full-text

Analysis of Risk Factors for Carbapenem-Resistant Klebsiella pneumoniae Infection and Its Effect on the Outcome of Early Infection After Kidney Transplantation

Frontiers in Cellular and Infection Microbiology ◽

10.3389/fcimb.2021.726282 ◽

2021 ◽

Vol 11 ◽

Author(s):

Fei Zhang ◽

Jinbiao Zhong ◽

Handong Ding ◽

Jiashan Pan ◽

Jing Yang ◽

...

Keyword(s):

Risk Factors ◽

Survival Rate ◽

Klebsiella Pneumoniae ◽

Postoperative Mortality ◽

Effective Prevention ◽

Carbapenem Resistant ◽

Kaplan Meier ◽

Total Prevalence ◽

One Year ◽

The One

BackgroundInfections remain a major cause of morbidity and mortality in kidney transplant (KT) recipients. This study was performed to identify the overall prevalence of early infections, prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) infection after KT, one-year postoperative mortality in patients with early infections and risk factors for CRKP infections.MethodsWe conducted a retrospective study of all patients who received KT in our hospital between January 2017 and December 2019. We evaluated the demographic, clinical, infection characteristics and the one-year postoperative outcomes.ResultsAmong the 419 patients who received KT between January 2017 and December 2019, 150 patients had at least one infection within 90 days after KT. The total prevalence of early infections was 36.1% (150/415), the prevalence of early CRKP infections was 10.4% (43/415), and the one-year postoperative mortality was 15.3% (23/150) in patients with early infections. The risk factors independently related to one-year postoperative mortality were mechanical ventilation (MV) > 48 h (Odds ratio (OR)= 13.879, 95%Confidence interval (CI): 2.265~85.035; P=0.004) and CRKP infection (OR=6.751, 95% CI: 1.051~43.369; P =0.044). MV> 48 h was independently related to CRKP infection (OR=3.719, 95% CI: 1.024~13.504; P=0.046). Kaplan-Meier survival curves showed that the one-year survival rate of patients infected with CRKP in the early postoperative stage was significantly lower than that of uninfected patients.ConclusionsIn general, the prevalence of early infections after KT is high, and CRKP infection is closely correlated with poor prognosis. The effective prevention and treatment of CRKP infection is an important way to improve the one-year survival rate after KT.

Download Full-text

A multicenter phase II study of S-1 plus ramucirumab as first-line treatment in elderly patients with advanced/recurrent gastric cancer (KSCC1701).

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.4043 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. 4043-4043

Author(s):

Hiroo Katsuya ◽

Koichi Suyama ◽

Kazuma Kobayashi ◽

Naoki Izawa ◽

Yoshikazu Uenosono ◽

...

Keyword(s):

Gastric Cancer ◽

Survival Rate ◽

Elderly Patients ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Recurrent Gastric Cancer ◽

One Year ◽

The One ◽

First Line Treatment

4043 Background: Elderly patients are often intolerable in the combination with cytotoxic agents. Therapy with S-1 alone is a key option for initial chemotherapy for Japanese elderly patients with unresectable gastric cancer in clinical practice. However, there are some cases in which the antitumor effects with S-1 alone are insufficient. We aimed to investigate the efficacy and safety of S-1 plus ramucirumab therapy to elderly patients with advanced/recurrent gastric cancer. Methods: Patients aged 70 years and older with previously untreated unresectable or recurrent gastric cancer patients were included in Japan. They received S-1 therapy (40-60 mg twice daily for 28 days, every 6 weeks) plus ramucirumab therapy (8 mg/kg, every 2 weeks) until disease progression. The primary endpoint was the one-year survival rate and null hypothesis of one-year survival was set as 40%, which is the lower bound of the 95% confidence interval in previously reported studies on S-1 therapy. The secondary endpoints included progression-free survival (PFS), overall survival (OS), response rate (RR), and safety. Results: Between September 2017 and November 2019, 48 patients were enrolled in this study. The characteristics of patients were male/female: 34/14, median age: 77.5 years (range: 71-87), and PS (0/1): 20/28. The one-year survival rate was 65.2% (95% confidence interval 49.8-78.6%), which means this trial met the primary endpoint. The median OS and PFS were 16.4 months (95%CI:12.0–20.7) and 5.8 months (95%CI:4.0–7.2), respectively. The best RR (CR+PR) was 60.9%. The frequent grade 3 or grade 4 adverse events were neutropenia (27.7%), anorexia (23.4%), anemia (19.1%), hypertension (14.9%), leucopenia (12.8%) and hypoalbuminemia (12.8%). Conclusions: Based on the observed efficacy and safety, S-1 plus ramucirumab is an appropriate first-line treatment for elderly patients with advanced/recurrent gastric cancer. Clinical trial information: UMIN000028309.

Download Full-text

A One-year Follow-up Study of a Tapered Hydrophilic Implant Design Using Various Placement Protocols in the Maxilla

The Open Dentistry Journal ◽

10.2174/1874210601610010680 ◽

2016 ◽

Vol 10 (1) ◽

pp. 680-691 ◽

Cited By ~ 4

Author(s):

Jakob Zwaan ◽

Leonardo Vanden Bogaerde ◽

Herman Sahlin ◽

Lars Sennerby

Keyword(s):

Survival Rate ◽

Bone Loss ◽

Implant Design ◽

Insertion Torque ◽

Daily Routine ◽

High Survival ◽

Marginal Bone Loss ◽

The Mean ◽

One Year

Purpose: To study the clinical/radiographic outcomes and stability of a tapered implant design with a hydrophilic surface when placed in the maxilla using various protocols and followed for one year. Methods: Ninety-seven consecutive patients treated as part of daily routine in two clinics with 163 tapered implants in healed sites, in extraction sockets and together with bone augmentation procedures in the maxilla were evaluated after one year in function. Individual healing periods varying from 0 to 6 months had been used. Insertion torque (IT) and resonance frequency analysis (RFA) measurements were made at baseline. Follow-up RFA registrations were made after 6 and 12 months of loading. The marginal bone levels were measured in intraoral radiographs from baseline and after 12 months. A reference group consisting of 163 consecutive straight maxillary implants was used for the comparison of baseline IT and RFA measurements. Results: Five implants failed before loading, giving an implant survival rate of 96.9% and a prosthesis survival rate of 99.4% after one year. The mean marginal bone loss after one year was 0.5 mm (SD 0.4). The mean IT was statistically significantly higher for tapered than for straight reference implants (41.3 ± 12.0 Ncm vs 33.6 ± 12.5 Ncm, p < 0.001). The tapered implants showed a statistically insignificantly higher mean ISQ value than the straight references implants (73.7 ± 6.4 ISQ vs 72.2 ± 8.0 ISQ, p=0.119). There was no correlation between IT and marginal bone loss. There was a correlation between IT and RFA measurements (p < 0.001). Conclusion: The tapered implant showed a high survival rate and minimal marginal bone loss after one year in function when using various protocols for placement. The tapered implant showed significantly higher insertion torque values than straight reference implants.

Download Full-text

Y-shaped Ventriculo-peritoneal Shunt for Adult Complicated Hydrocephalus: Report of 28 Illustrative Cases

10.21203/rs.3.rs-94549/v1 ◽

2020 ◽

Author(s):

Xiaohui Ren ◽

Chuanwei Yang ◽

Xiangrong Li ◽

Yonggang Wang ◽

Song Lin

Keyword(s):

Survival Rate ◽

Cox Regression ◽

Tumor Resection ◽

Long Term Outcome ◽

Frontal Horn ◽

First Choice ◽

Multiloculated Hydrocephalus ◽

One Year ◽

The One ◽

Ventriculo Peritoneal Shunt

Abstract ObjectiveTo investigate the effectiveness of Y-shaped ventriculo-peritoneal shunt (VPS) (one abdominal tip connected with double or triple ventricular tips by one or two Y-shaped connectors) in the treatment of adult complicated hydrocephalus, we analyzed the long-term outcome and reported some illustrative cases.MethodsAmong 1,100 VPS surgeries between 2012 and 2017 in neurosurgery of Beijing Tiantan Hospital, twenty-eight (2.5%) adult patients with multiloculated hydrocephalus treated with Y-shaped shunt were analyzed.ResultsNineteen patients underwent Y-shaped VPS (bilateral frontal horn shunt) before or without tumor resection/stereotactic biopsy, 7 patients underwent Y-shaped VPS after tumor resection (5 bilateral and 2 triple shunts), and the other 2 patients underwent sequential bilateral VPS (unilateral VPS with additional contralateral ventricular tip by Y-shaped connector 6 months later). The one-year and two-year hydrocephalus-free survival rate for was both 88.7%. The one-year and two-year overall survival rate was both 66.7%. Cox regression confirmed that the OS is correlated with tumor grades. ConclusionsY-shaped VPS strategy is an easy and reliable option for multiloculated hydrocephalus, which can be used as the first choice for some indications.

Download Full-text

Treatment of advanced-stage ovarian cancer including combination of intra-abdominal chemotherapy

Уральский медицинский журнал ◽

10.52420/2071-5943-2021-20-2-28-35 ◽

2021 ◽

Vol 20 (2) ◽

pp. 28-35

Author(s):

V. V. Saevets ◽

A. V. Privalov ◽

A. V. Vazhenin ◽

Y. A. Semenov ◽

A. V. Shmidt

Keyword(s):

Ovarian Cancer ◽

Survival Rate ◽

Abdominal Cavity ◽

Relative Survival ◽

Study Groups ◽

Stage Iiia ◽

Results Of Treatment ◽

Significant Difference ◽

One Year ◽

The One

Introduction. Ovarian cancer is the leading cause of death from gynecological malignancies: the one-year relative survival rate with stages 3 and 4 of the disease is 20%. The results of treatment remain unsatisfactory, which dictates the need to find new methods of treatment. The aim of the study was to evaluate the effectiveness of the use of HIIH (hyperthermic intraperitoneal intraoperative chemoperfusion, HIPEC) in patients with the diagnosis of: ovarian cancer IIIA-From the stage of the disease.Materials and methods. 117 cases of stage IIIA-C ovarian cancer treated at the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine from January 2014 to March 2021 were retrospectively studied. All patients underwent 3 cycles of neoadjuvant chemotherapy (NAPHT) according to the paclitaxel+carboplatin (PCb) scheme, followed by surgical treatment to the extent of maximum cytoreductive surgery. Two study groups were formed: 1 — cases with GIIH (N=57), 2-without GIIH (N=60). On the 14-16 day after the operation, all patients underwent 3 cycles of adjuvant chemotherapy according to the PCb scheme.Results. A significant increase in overall survival was found in the first group of patients with HIPEC. This technique allows to increase the survival rate of patients for 14 months at stage IIIA-B (p<0.05). At stage IIIC, there was no statistically significant difference in the survival rate of patients. There was a tendency to increase the survival rate by 5 months (p>0.05), which is associated with the pronounced prevalence of the tumor process and the technical impossibility of removing the tumor. Discussion. The concentration of drugs in the abdominal cavity and in the blood plasma significantly differs due to the functioning of the peritoneal-plasma barrier, which leads to a lower toxicity in comparison with systemic chemotherapy, and therefore allows you to give a large dose of the drug with fewer adverse events, and the fact of hyperthermia (42°C) has a positive effect on the effectiveness of intraperitoneal chemotherapy. To date, this method has not been included in the clinical recommendations on the territory of the Russian Federation, but data from foreign literature, including randomized trials, have shown the high effectiveness of this method.Conclusion. The results obtained in the course of our study demonstrate the effectiveness of this technique, in the form of an increase in overall and relapse-free survival with acceptable toxicity.

Download Full-text

Clinicopathological findings and imaging features of intraductal papillary neoplasms in bile ducts

PeerJ ◽

10.7717/peerj.10040 ◽

2020 ◽

Vol 8 ◽

pp. e10040

Author(s):

Honghui Zhang ◽

Zhendong Zhong ◽

Gaoyin Kong ◽

Junaid Khan ◽

Lianhong Zou ◽

...

Keyword(s):

Risk Factor ◽

Survival Rate ◽

Independent Risk Factor ◽

Malignant Tumors ◽

Univariate Analysis ◽

Benign Tumors ◽

Differentiation Degree ◽

One Year ◽

The One ◽

Malignant Ipmn

Background Intraductal papillary mucinous neoplasm of the bile duct (IPMN-B) is considered an uncommon tumor, and there is limited understanding of IPMN-B. This study aimed to investigate the prognosis and influential factors of the IPMN-B from 58 cases. Methods The clinical data of 58 patients with pathologically confirmed IPMN-B admitted to our hospital from January 1, 2012 to August 2017 were collected and analyzed. The patients were followed up by outpatient or telephone until January 1, 2019. SPSS 19.0 software was applied for data analysis. Survival analysis was performed using Kaplan-Meier method and parallel Log-rank test. Prognostic factors were analyzed by univariate analysis and multiple Cox regression model. Results Among of all the patients, 26 cases were benign tumors and 32 cases were malignant tumors. The preoperative tumor markers CA242 and CEA of malignant IPNM-B patients were significantly higher than those in benign tumors (P < 0.05). Survival analysis showed that patients with malignant tumors had a worse prognosis. The median survival time of malignant IPMN-B patients was 40.6 ± 3.0 months, yet median survival time of benign IPMN-B patients was not reached (P = 0.19). The one-year survival rate and three-year survival rate of benign IPMN-B were 84% and 74% respectively. The one-year survival rate and three-year survival rate of malignant IPMN-B were 88% and 64% respectively. Univariate analysis showed that combined lymph node metastasis, surgical method, and differentiation degree could affect patients’ prognosis (P < 0.05). Multivariate analysis showed differentiation degree was an independent risk factor affecting prognosis (OR = 0.06, 95% confidence interval: 0.007∼0.486, P < 0.05). Conclusion The levels of CEA and CA242 were helpful to identify benign and malignant of IPNM-B. Moreover, radical surgical resection could prolong patients’ survival. Finally, differentiation degree was an independent risk factor affecting malignant IPNM-B prognosis.

Download Full-text

The Investment Attractiveness of Regions as One of Entrepreneurship Development Factors

Economic and Regional Studies / Studia Ekonomiczne i Regionalne ◽

10.2478/ers-2020-0012 ◽

2020 ◽

Vol 13 (2) ◽

pp. 170-183

Author(s):

Izabella Sikorska-Wolak ◽

Jan Zawadka ◽

Krystyna Krzyżanowska

Keyword(s):

Survival Rate ◽

Considerable Influence ◽

Enterprise Development ◽

Entrepreneurship Development ◽

The Subject ◽

Using Data ◽

One Year ◽

The One ◽

Desk Research ◽

Market Economics

SummarySubject and purpose of work: The subject of the paper is entrepreneurship development and its determinants, with particular attention to the investment attractiveness of Polish provinces. The purpose of the paper is to identify the level of entrepreneurship development (between 2009 and 2017) and investment attractiveness (between 2009 and 2016) of individual provinces, and to define the correlation between the two features.Materials and methods: The authors of this paper analysed the literature on the subject and performed desk research using data from reports and studies published by GUS (Statistics Poland), PAPR (Polish Agency for Enterprise Development) and IBnGR (Gdańsk Institute for Market Economics).Results: In 2017, the number of SMEs* in Poland increased by over 24% in relation to 2009. The results showed a significant inversely proportional correlation between the number of enterprises per 1000 inhabitants and the one-year survival rate for the enterprises. The investment attractiveness of provinces was diverse. The level of investment attractiveness exerted a considerable influence on enterprise development in individual provinces.Conclusions: The results of the study showed that both the investment attractiveness and entrepreneurship are diverse in individual regions. A significant correlation was found between these two phenomena. Some exceptions to the rule were identified, which can be explained by divergence.

Download Full-text

THE ROLE OF TRANSARTERIAL CHEMOEMBOLIZATION IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN THE STAGE B OF BCLC

10.35805/kazsurgeryvhk2019(59)216 ◽

2019 ◽

pp. 37-42

Author(s):

Talgat Tajibaev ◽

Bolatbek Baimakhanov ◽

Ulugbek Medeubekov ◽

Shokan Kaniev ◽

Bekzhan Issamatov

Keyword(s):

Hepatocellular Carcinoma ◽

Survival Rate ◽

Transarterial Chemoembolization ◽

Survival Curve ◽

Intermediate Stage ◽

Kaplan Meier ◽

Contrast Enhanced Ct ◽

Number Of Patients ◽

One Year ◽

The One

Hepatocellular carcinoma is the most common primary tumor pathology of the liver (> 85%), an aggressive course with an unfavorable prognosis. Objective: To analyze the results of transarterial chemoembolization in the intermediate stage of hepatocellular carcinoma. Materials and methods: The study was conducted on the basis of the JSC “National Scientific Center of Surgery” named after A.N. Syzganov in the period 2013-2018. Statistical calculations were performed using Excel, SPSS Statistics by estimating the survival rate using the Kaplan-Meier method. Results: The study included 58 patients with HCC in the B stage of BCLC. The average age of the patients was 60.4 years. The follow-up period was 6–64 months. In 42 patients, the test results for viral hepatitis were positive. 58 patients underwent 103 TACE interventions. After chemoembolization, 8 patients subsequently underwent surgery (liver resection). The one-year survival after TACE in the total cohort was 42%, 2-year - 15% and 3-year - 5%, respectively. In patients older than 60 and 70 years, the 3-year and 5-year survival rates were 0%, the one-year survival rate of the subjects studied in the group over 70 years old was 14.3%. The survival rate among patients in stage B on the Chile-Pugh scale was significantly lower to patients in stage A (82% versus 56% for 6 months and 50% versus 31% for the year, respectively). Statistically significant differences were found in the group with a substantial increase in AFP (> 1000 IU / ml), the Kaplan-Meier survival curve showed a survival rate of 0% after 18 months since the first TACE. Six months after TACE contrast enhanced CT was performed on 36 patients, of which 15 patients showed positive dynamics, in the form of a reduction in size or transformation of the formation, in 6 patients a negative dynamics in the form of an increase in the size of the formation. Conclusion: Despite the small number of patients studied, TACE showed good results in the intermediate stage of HCC. Elderly and senile age, a high degree of liver dysfunction, as well as high AFP values are additional factors that dramatically reduce the life expectancy of patients after TACE with HCC in stage B-BCLC.

Download Full-text